RESOLUTE and REsolution Final Conference on 27-29 September 2023
From 27 to 29 September 2023, the 'Unlocking Transporters for Drug Discovery' Conference took place at the historic Palais Niederösterreich in Vienna, Austria. The event, open for the first time to the entire scientific community, marked the conclusion of the RESOLUTE and REsolution projects, which are set to conclude by the end of 2023. The REsolution and RESOLUTE consortia are public-private research partnerships supported by the Innovative…
Thomas Reiberger and Laura de Rooij received the prestigious LBG CRG funding for their project "MOTION"
Congratulations to CeMM Adjunct Principal Investigator Thomas Reiberger and CeMM Principal Investigator Laura de Rooij, who received the prestigious CRG funding from the Ludwig Boltzmann Gesellschaft for their project entitled "Disease-Driving Mechanisms in Patients with Portal Hypertension," in short "MOTION"! Portal Hypertension (PH) is a severe consequence of liver diseases, causing more than 2 million (4% of all) deaths worldwide each year.…
Johanna Strobl awarded the ÖGAI Karl Landsteiner Prize 2023
Congratulations to Johanna Strobl, a postdoc in the group of CeMM Adjunct Principal Investigator Georg Stary at the Medical University of Vienna, for receiving the Karl Landsteiner Prize in basic immunological research in 2023! Every year, the Austrian Society for Allergology and Immunology (ÖGAI) and the Karl Landsteiner and Eisler-Terramare Private Memorial Foundation (Bio&Bio) present this award in honor of the significant contributions of…
Clarissa Campbell and Barbara Maier at CeMM receive ERC Starting Grants
Two scientists at the CeMM have received prestigious ERC Starting Grants from the European Commission: Clarissa Campbell and Barbara Maier. In Clarissa Campbell's laboratory, researchers are working to better understand the interplay between the immune system and metabolism. Barbara Maier and her team are researching the role of lymph nodes in the context of cancer. The ERC grants are among the most prestigious and competitive research grants…
Network-based approaches open a new avenue to classify and treat rare diseases
Scientists at CeMM, Max Perutz Labs, and St. Anna Children’s Cancer Research Institute have achieved a significant advancement in the research of rare immune system disorders. Through a network-based approach, they have reclassified approximately 200 rare diseases. Initial comparisons with clinical data already demonstrate how this can enhance the prediction of treatment efficacy. Moreover, the study reveals for the first time the strong…
Gene mutation in the immune system: Anti-diabetes drugs make immune cells more effective again
T cells are an essential component of the immune system - they fight foreign structures such as bacteria and viruses or cancer-related changes in cells. This defense reaction requires energy. Scientists led by the St. Anna Children's Cancer Research Institute and the Marmara University Istanbul have now shown for the first time that a defect in the gene for the transcription factor NFATC1 leads to an immune defect with a disruption of metabolism…
CeMM Receives HR Excellence in Research Award from the EU Commission
CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences (ÖAW), has been awarded the HR Excellence in Research Award from the European Commission. This recognition comes as a result of CeMM’s longstanding efforts to create the best possible conditions for top-tier scientists from around the world. Outstanding and innovative research is made possible through structurally optimal conditions, and with the HR Excellence…
New inhibitor for regulating the essential protein SMNDC1
The SMNDC1 gene controls key functions in the human body and is linked to diseases such as diabetes and cancer. Scientists in Stefan Kubicek’s research group at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences have successfully pinpointed the exact location of the SMNDC1 protein within the cell nucleus and identified an inhibitor that opens up the potential for therapeutic applications of SMNDC1. The study has…
New method enabling therapeutical targeting of lactate transporters
Scientists from the Giulio Superti-Furga Lab at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have developed a new method that allowed the discovery of specific inhibitors of a lactate transporter that is associated with cancer and other diseases areas. The compound identified in the assay system could provide a new starting point for cancer treatments. The study was now published in Cell Chemical…
Cardiovascular disease: key molecular pathway affecting atherosclerosis progression discovered
Heart attacks and strokes arising from atherosclerosis, which is driven by the accumulation of lipids in the inner linings of arteries, are responsible for about one third of deaths worldwide. Accordingly, atherosclerosis is the focus of intense research aimed at the development of novel effective treatments. A team of researchers from MedUni Vienna has now described a key molecular pathway that provides new fundamental insights into the…
11th CeMM S.M.A.R.T. Lecture with Prof. Oskar Aszmann
On 24 July 2023, CeMM hosted its 11th S.M.A.R.T. Lecture with Oskar Aszmann, Professor at the Medical University of Vienna. As the Director of the Center of Bionic Extremity Reconstruction and Vice-chair of the Department of Plastic and Reconstructive Surgery at the Medical University of Vienna, Professor Aszmann and his team have been at the forefront of pioneering bionic reconstruction, setting remarkable milestones, including advancements in…
CeMM Scientific Recess 2023
From 3-5 July2023, the CeMM Recess 2023 took place in Altlengbach (Austria). This year, the overarching theme was to foster collaborations between CeMM and Adjunct Groups by presenting “What’s in my fridge”. The objective was to share methods, skills, knowledge, and data with colleagues to generate new ideas and promising projects. Our guest speakers and CeMM Alumni members Berend Snijder, Professor at the ETH Zurich, and Ariel Bensimon, CEO of…
Newly discovered genetic defect disrupts blood formation and immune system
In the quest to find the origin of the puzzling symptoms in four children, researchers from St. Anna Children's Cancer Research Institute, the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (ÖAW), and the Medical University of Vienna have discovered a completely new disease, linking disruptions of blood formation, the immune system, and inflammation. This groundbreaking discovery provides the basis for a better…
CeMM receives the German Brand Award 2023
CeMM has been honored with the German Brand Award in the category of Excellence in Brand Strategy and Creation in the field of Education & Research! In 2022, after 15 years of exceptional research and growth, we knew it was time to adapt our corporate identity to reflect our progress and achievements. We embarked on a collaborative effort with our talented team of scientists, administration, and alumni to highlight CeMM's identity, values, and…
4th REsolution Consortium Meeting
On 12 June 2023, the REsolution consortium held its fourth and final consortium meeting. The event took place at CeMM with 20 participants coming from different countries and 5 participants joining virtually. The REsolution consortium is a public-private research partnership supported by the Innovative Medicines Initiative (IMI), EU and EFPIA with 9 partners from academia and the pharmaceutical industry. The project has a duration of 2 years and…
